Bhaskar Dasgupta, ACR 2022: The SAPHYR study of sarilumab in polymyalgia rheumatica

SAPHYR (NCT03600818) was a randomized, double-blind, placebo-controlled phase 3 study, investigating the efficacy and safety of sarilumab in polymyalgia rheumatica. In this interview with Prof. Bhaskar Dasgupta (Southend University Hospital NHS Foundation Trust, Southend-on-Sea, UK) we discussed the aims, design, eligibility criteria and findings of the study.

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.

The abstract ‘Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)‘ (Abstract number: 1676) was presented at the ACR Convergence, November 10–14, 2022.

Questions

1. What is the rationale for the use of sarilumab in the treatment of PMR?
2. What were the aims, design and eligibility criteria of the SAPHYR study? (1:18)
3. What was the primary endpoint of the study and how well was it achieved? (4:49)
4. What were the safety and quality of life findings of the study? (6:11)

Disclosures: Bhaskar Dasgupta discloses consulting for Sanofi; receiving grant/ research support from Sanofi; and receiving honoraria from Sanofi.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.

Filmed in coverage of the ACR Convergence 2022.